Add to ORKGThere is no evidence that anticoagulation with warfarin, initiated after a non- cardioembolic ischemic stroke, significantly reduces stroke recurrence. Furthermore, anticoagulation significantly increases the risk of fatal and nonfatal hemorrhagic stroke and extracranial hemorrhage in these patients. However, warfarin clearly is indicated for patients who have embolic strokes caused by underlying conditions such as atrial fibrillation or myxoma. (Strength of recommendation: A
HMG Co-A reductase inhibitors (statins) are effective for primary prevention of ischemic stroke in p...
<b><i>Background and Purpose:</i></b> WARCEF randomized 2,305 patients in sinus rhythm with ejection...
Background. Atrial fibrillation in the absence of rheumatic valvular disease is associated with a fi...
Background: Despite the use of antiplatelet agents, usually aspirin, in patients who have had an isc...
Abstract Introduction: For many years, warfarin was the drug of choice for ischemic stroke patients ...
Anticoagulation therapy with warfarin is not indicated for use in patients with non- valvular atrial...
BACKGROUND: Embolic strokes of undetermined source represent 20% of ischemic strokes and are associ...
et al.1 examined the risk of hemorrhagic stroke in patients treated with antithrombotics. While warf...
The aims of this article are to review the evidence regarding the use of non-vitamin K oral anticoag...
OBJECTIVE: To compare the effectiveness of aspirin, warfarin, and ximelagatran as thromboprophylaxis...
BACKGROUND AND PURPOSE: WARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF)...
Background Embolic strokes of undetermined source represent 20% of ischemic strokes and are associat...
Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its u...
Background: Atrial fibrillation (AF) is one of the commonest of cardiac arrhythmia. Non-valvular atr...
Background and purposeWARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF) ≤...
HMG Co-A reductase inhibitors (statins) are effective for primary prevention of ischemic stroke in p...
<b><i>Background and Purpose:</i></b> WARCEF randomized 2,305 patients in sinus rhythm with ejection...
Background. Atrial fibrillation in the absence of rheumatic valvular disease is associated with a fi...
Background: Despite the use of antiplatelet agents, usually aspirin, in patients who have had an isc...
Abstract Introduction: For many years, warfarin was the drug of choice for ischemic stroke patients ...
Anticoagulation therapy with warfarin is not indicated for use in patients with non- valvular atrial...
BACKGROUND: Embolic strokes of undetermined source represent 20% of ischemic strokes and are associ...
et al.1 examined the risk of hemorrhagic stroke in patients treated with antithrombotics. While warf...
The aims of this article are to review the evidence regarding the use of non-vitamin K oral anticoag...
OBJECTIVE: To compare the effectiveness of aspirin, warfarin, and ximelagatran as thromboprophylaxis...
BACKGROUND AND PURPOSE: WARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF)...
Background Embolic strokes of undetermined source represent 20% of ischemic strokes and are associat...
Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its u...
Background: Atrial fibrillation (AF) is one of the commonest of cardiac arrhythmia. Non-valvular atr...
Background and purposeWARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF) ≤...
HMG Co-A reductase inhibitors (statins) are effective for primary prevention of ischemic stroke in p...
<b><i>Background and Purpose:</i></b> WARCEF randomized 2,305 patients in sinus rhythm with ejection...
Background. Atrial fibrillation in the absence of rheumatic valvular disease is associated with a fi...